Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Merck Canada Inc.

Anastasia G Daifotis

Arthur C Santora, Ii

A John Yates

Cameron Black

Ashley J Yates

Selwyn Aubrey Stoch

Basil Avery Ince

The present invention relates to the a method of inhibiting bone resorption in a mammal in need thereof with an oral pharmaceutical composition comprising a cathepsin K inhibitor, or a pharmaceutically acceptable salt thereof, or a mixture thereof, according to a continuous schedule having a dosage interval of once weekly, biweekly, twice monthly or once monthly.

Composition for inhibition of cathepsin K

Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for carrying out the therapeutic methods disclosed herein.

Method for inhibiting bone resorption

Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for caring out the therapeutic methods disclosed herein.

Bisphosphonate, particularly alendronate, can prevent or treat bone loss associated with immunosuppressive therapy, whether or not the immunosuppressive therapy is associated with an organ transplant.

Growing community of inventors

Westfield, NJ, United States of America

Anastasia G Daifotis